Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

Inclusion Criteria: * Male or female (post-menopausal and/or surgically sterile) * Aged 18 to 70 years * Diagnosed with type 2 diabetes mellitus of eight years or less in duration * Being treated with OAD at stable maximum doses \[defined as at least 10 mg/day glibenclamide (preferred), or 20 mg/day glipizide, with or without at least 1,500 mg/day metformin\] for at least three months prior to screening * Having fasting plasma glucose levels of 150-270 mg/dL and HbA1c levels of 7.5-11.0% Exclusion Criteria: * Greater than 3 severe hypoglycemic episodes within six months of screen * Pregnant, breastfeeding, or intends to become pregnant * Clinical signs or symptoms of liver disease, acute, or chronic hepatitis, or ALT greater than the upper limit of normal * Positive hepatitis B surface antigen, hepatitis C antibody, or HIV test * Patients with history of renal transplantation or renal dialysis or microalbuminuria defined as urine albumin \> 200 mg/day * History of insulin use within three months of screen * History of diabetic ketoacidosis * Treatment with any thiazolidinedione (e.g., rosiglitazone) within three months of screen * History of lactic acidosis while on metformin therapy * Complications of diabetes (e.g., neuropathy, nephropathy, and retinopathy) * Clinically significant and currently active diseases * Clinical significant abnormalities in medical history, physical examination, or laboratory examination